OCT 21, 2019 10:32 PM PDT

Therapeutic Targets Inflammation Associated with Genetic Heart Disease

WRITTEN BY: Nouran Amin

Often times when young athletes collapse during the game it is due to sudden cardiac death as a result of the inherited arrhythmogenic cardiomyopathy (ACM). Researchers have sought a new drug that can help reduce some of the ACM disease symptoms and progression to heart failure in affected individuals. The drug is referred to as ‘Bay-11-7082’ and is currently used in laboratory settings for experimental purposes.

Learn more:

"We realized that heart muscle inflammation in ACM is much more complicated than we thought, but also might provide a therapeutic strategy," says Stephen Chelko, Ph.D., assistant professor of medicine at the Johns Hopkins University School of Medicine.

ACM patients carry mutations in any of the five genes that are involved with holding the heart cells together. If an individual is aware that they carry such mutations, they are warned to avoid certain exercises and are placed on particular diets. Although some drugs are prescribed to maintain a slower heart rate, there are currently none that target the underlying defects of ACM.

"We tended in the past to view ACM as something that kills due to a sudden arrhythmic event," said Chelko. "But now we're starting to also see it as a chronic inflammatory disease that can progress more slowly over time, leading to heart failure."

Researchers have examined the molecular origins of heart inflammation in people with ACM. Findings, published in Circulation, shows that inflammation is a result of two separate causes: the high levels of an immune cell known as macrophages, a type of immune cell that's normally found at sites of inflammation and the presence of protein nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB).

A healthy mouse heart (left), a mouse heart with cardiomyopathy (center) and a mouse heart with cardiomyopathy treated with the NF-κB-blocking drug Bay-11-7082 (right).

Credit: Circulation via HopkinsMedicine.org

"Macrophages are usually the good guys who help heal a wound and then leave," said Chelko. "But in ACM they're permanently setting up shop in the heart, which, over time, reduces its function. We're very excited to have found an FDA-approved drug that can reduce heart inflammation in ACM, and we're eager to do more research to ultimately help those who carry these genetic mutations.”

Story Source: Johns Hopkins Medicine

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 09, 2019
Drug Discovery & Development
DEC 09, 2019
Could the diabetic drug 'metformin' extend a healthy lifespan?
The most commonly prescribed diabetic medication for the Type 2 condition is ‘Metformin’—a drug with a mysterious mechanism of action but...
DEC 12, 2019
Drug Discovery & Development
DEC 12, 2019
Probiotics Treat Alcohol-Induced Liver Injury
Alcoholic liver injury is caused by overconsumption of alcohol, something that can lead to serious diseases such as liver steatosis, liver cirrhosis and li...
DEC 22, 2019
Genetics & Genomics
DEC 22, 2019
New Gene Therapy Uses Exosomes to Reverse Disease
Researchers at Ohio State University have developed a new gene therapy that makes use of exosomes, fluid sacs released in cells, to carry therapeutic tools...
DEC 27, 2019
Drug Discovery & Development
DEC 27, 2019
Acne Drug Linked to 10 Suicides
UK regulators claim to have found a link between at least ten suicides and a powerful acne drug, manufactured under the names Roaccutane and Accutane. Alth...
JAN 15, 2020
Drug Discovery & Development
JAN 15, 2020
A New Drug Target for Substance Abuse
Research carried out by the University of Minnesota Medical School indicates a new drug target for treating a drug addiction. Researchers note that the dru...
FEB 27, 2020
Drug Discovery & Development
FEB 27, 2020
New Drug Shows Promise in Treating Chronic Cough
Between 4% and 10% of adults around the world have an unexplainable chronic cough that has lasted for over 8 weeks. Although no treatments are currently av...
Loading Comments...